Financial Comparison
AbbVie Inc. vs Pfizer Inc
Click a ticker to view the full analysis.
ABBV vs
In short
Pfizer Inc is the more profitable of the two, keeping 12.4% of revenue as net profit against 6.9% for AbbVie Inc. AbbVie Inc. trades at the higher trailing P/E (77.0× vs 36.6× for Pfizer Inc), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for AbbVie Inc. and 1 for Pfizer Inc.
Based on filings for periods ending 30 Jun 2026 (ABBV) and 28 Jun 2026 (PFE) · Updated
FisclearScore Comparison
ABBV65Strong
PFE61Fair
Quality+21
74
53
Efficiency+15
70
55
Value+33
39
72
Cashflow+3
83
80
Regime
55
55
Peers+14
64
50
FisclearScore is a quantitative model. ABBV shown solid · PFE shown dashed. Not financial advice.
| Metric | ABBV | PFE |
|---|---|---|
| Price | $272.42 | $27.82 |
| Market Cap | $481.4B | $158.6B |
| P/E (TTM) | 77.0x | 36.6x |
| P/B | — | 1.9x |
| Beta | 0.23 | 0.28 |
| Div Yield | 2.46% | 6.06% |
| Revenue (TTM) | $61.2B | $62.6B |
| Net Income | $4.2B | $7.8B |
| Gross Margin | — | — |
| Risk Flags | 2 flags | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.